We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
ATRION Corporation | NASDAQ:ATRI | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-11.93 | -2.79% | 414.95 | 320.00 | 511.78 | 431.98 | 414.67 | 426.96 | 36,813 | 22:30:00 |
Atrion
Corporation
|
||
(Exact
Name of Registrant as Specified in its Charter)
|
||
|
|
|
Delaware
|
|
63-0821819
|
(State
or Other Jurisdiction of Incorporation or
Organization)
|
|
(I.R.S.
Employer Identification No.)
|
|
|
|
One
Allentown Parkway, Allen, Texas 75002
|
||
(Address of
Principal Executive Offices) (Zip
Code)
|
||
(972)
390-9800
|
||
(Registrant’s
Telephone Number, Including Area Code)
|
Title
of Each Class
|
|
Number
of Shares Outstanding at
April
20, 2018
|
Common
stock, Par Value $0.10 per share
|
|
1,851,842
|
PART I. Financial Information
|
|
3
|
||
|
|
|
|
|
|
Item 1. Financial Statements
|
|
3
|
|
|
|
|
|
|
|
|
Consolidated
Statements of Income (Unaudited) For the Three months Ended March
31, 2018 and 2017
|
|
3
|
|
|
|
|
|
|
|
Consolidated
Statements of Comprehensive Income (Unaudited) For the Three months
Ended March 31, 2018 and 2017
|
|
4
|
|
|
|
|
|
|
|
Consolidated
Balance Sheets (Unaudited)
March
31, 2018 and
December 31, 2017
|
|
5
|
|
|
|
|
|
|
|
Consolidated
Statements of Cash Flows (Unaudited) For the Three Months Ended
March 31, 2018 and 2017
|
|
6
|
|
|
|
|
|
|
|
Consolidated
Statement of Changes in Stockholders’ Equity (Unaudited)
March
31, 2018 and
December 31, 2017
|
|
7
|
|
|
|
|
|
|
|
Notes
to Consolidated Financial Statements (Unaudited)
|
|
8
|
|
|
|
|
|
|
Item 2.
Management's Discussion and Analysis of Financial Condition and
Results of Operations
|
|
16
|
|
|
|
|
|
|
|
Item 3
.
Quantitative
and Qualitative Disclosures About Market Risk
|
|
19
|
|
|
|
|
|
|
|
Item
4.
Controls and
Procedures
|
|
20
|
|
|
|
|
|
|
PART II. Other Information
|
|
20
|
||
|
|
|
|
|
|
Item 1.
Legal Proceedings
|
|
20
|
|
|
|
|
|
|
|
Item 1A.
Risk Factors
|
|
20
|
|
|
|
|
|
|
|
Item 6. Exhibits
|
|
20
|
|
|
|
|
|
|
SIGNATURES
|
|
20
|
||
|
|
|
|
|
Exhibit Index
|
|
21
|
|
Three Months Ended March 31,
|
|
|
2018
|
2017
|
|
(In
thousands)
|
|
|
|
|
Net
Income
|
$
8,487
|
$
9,950
|
|
|
|
Other Comprehensive
Loss
Unrealized loss on
investments, net of tax benefit
of $169 in
2017
|
--
|
(313
)
|
|
|
|
Comprehensive
Income
|
$
8,487
|
$
9,637
|
Assets
|
March
31,
2018
|
December
31,
2017
|
|
(in
thousands)
|
|
Current assets:
|
|
|
Cash and cash
equivalents
|
$
20,181
|
$
30,136
|
Short-term
investments
|
34,795
|
35,468
|
Accounts
receivable
|
20,604
|
17,076
|
Inventories
|
29,907
|
29,354
|
Prepaid expenses
and other current assets
|
2,064
|
3,199
|
|
107,551
|
115,233
|
|
|
|
Long-term
investments
|
23,953
|
9,136
|
|
|
|
Property, plant and
equipment
|
170,313
|
167,080
|
Less accumulated
depreciation and amortization
|
102,828
|
100,711
|
|
67,485
|
66,369
|
|
|
|
Other assets and
deferred charges:
|
|
|
Patents
|
1,748
|
1,778
|
Goodwill
|
9,730
|
9,730
|
Other
|
1,786
|
1,534
|
|
13,264
|
13,042
|
|
|
|
Total
assets
|
$
212,253
|
$
203,780
|
Liabilities
and Stockholders’ Equity
|
|
|
Current
liabilities:
|
|
|
Accounts payable
and accrued liabilities
|
$
8,208
|
$
8,876
|
Accrued income and
other taxes
|
2,975
|
746
|
|
11,183
|
9,622
|
|
|
|
Line of
credit
|
--
|
--
|
|
|
|
Other non-current
liabilities
|
10,102
|
9,770
|
|
|
|
Stockholders’
equity:
|
|
|
Common stock, par
value $0.10 per share; authorized10,000 shares, issued 3,420
shares
|
342
|
342
|
Paid-in
capital
|
49,044
|
48,730
|
Accumulated other
comprehensive loss
|
--
|
(1,215
)
|
Retained
earnings
|
273,240
|
268,194
|
Treasury
shares,1,584 at March 31, 2018 and 1,584 at December 31, 2017, at
cost
|
(131,658
)
|
(131,663
)
|
Total
stockholders’ equity
|
190,968
|
184,388
|
|
|
|
|
|
|
Total
liabilities and stockholders’ equity
|
$
212,253
|
$
203,780
|
|
Common
Stock
|
Treasury
Stock
|
|
|
|
|
||
|
Shares
Outstanding
|
Amount
|
Shares
|
Amount
|
Additional
Paid-in Capital
|
Accumulated
Other Comprehensive Income (Loss)
|
Retained
Earnings
|
Total
|
Balances, January
1, 2017
|
1,836
|
$
342
|
1,584
|
$
(131,663
)
|
$
48,730
|
$
(1,215
)
|
$
268,194
|
$
184,388
|
|
|
|
|
|
|
|
|
|
Net
income
|
|
|
|
|
|
|
8,487
|
8,487
|
Reclass
from adopting ASU 2016-01
|
|
|
|
|
|
1,215
|
(1,215
)
|
--
|
Stock-based
compensation transactions
|
|
|
|
5
|
314
|
|
|
319
|
Dividends
|
|
|
|
|
|
|
(2,226
)
|
(2,226
)
|
Balances, March 31,
2018
|
1,836
|
$
342
|
1,584
|
$
(131,658
)
|
$
49,044
|
$
0
|
$
273,240
|
$
190,968
|
|
March
31,
|
December
31,
|
|
2018
|
2017
|
Raw
materials
|
$
13,715
|
$
13,545
|
Work in
process
|
7,127
|
6,647
|
Finished
goods
|
9,065
|
9,162
|
Total
inventories
|
$
29,907
|
$
29,354
|
|
|
|
Gross
Unrealized
|
|
|
|
Level
|
Cost
|
Gains
|
Losses
|
Fair
Value
|
As
of March 31, 2018:
|
|
|
|
|
|
Short-term
Investments
|
|
|
|
|
|
Certificates of
deposit
|
2
|
4,036
|
$
--
|
$
(10
)
|
$
4,026
|
Commercial
paper
|
2
|
20,912
|
$
--
|
$
(40
)
|
$
20,872
|
Bonds
|
2
|
9,847
|
$
--
|
$
(23
)
|
$
9,824
|
|
|
|
|
|
|
Long-term
Investments
|
|
|
|
|
|
Bonds
|
2
|
20,251
|
$
--
|
$
(215
)
|
$
20,036
|
Mutual
funds
|
1
|
352
|
$
--
|
$
(8
)
|
$
344
|
Equity
investments
|
2
|
5,675
|
$
--
|
$
(2,317
)
|
$
3,358
|
|
|
|
|
|
|
As
of December 31, 2017:
|
|
|
|
|
|
Short-term
Investments
|
|
|
|
|
|
Certificates of
deposit
|
2
|
4,020
|
$
--
|
$
(3
)
|
$
4,017
|
Commercial
paper
|
2
|
31,220
|
$
26
|
$
(38
)
|
$
31,208
|
Bonds
|
2
|
6
|
$
--
|
$
--
|
$
6
|
Mutual
funds
|
1
|
219
|
$
3
|
$
--
|
$
222
|
|
|
|
|
|
|
Long-term
Investments
|
|
|
|
|
|
Bonds
|
2
|
5,000
|
$
--
|
$
(75
)
|
$
4,925
|
Equity
investments
|
2
|
5,675
|
$
--
|
$
(1,539
)
|
$
4,136
|
March 31,
2018
|
December 31,
2017
|
||||
Weighted
Average Original Life (years)
|
Gross Carrying
Amount
|
Accumulated
Amortization
|
Weighted
Average Original Life (years)
|
Gross Carrying
Amount
|
Accumulated
Amortization
|
15.67
|
$
13,840
|
$
12,092
|
15.67
|
$
13,840
|
$
12,062
|
2019
|
|
$119
|
2020
|
|
$119
|
2021
|
|
$119
|
2022
|
|
$117
|
2023
|
|
$113
|
|
2018
|
2017
|
United
States
|
$
24,607
|
$
23,105
|
Germany
|
2,671
|
3,037
|
Other countries
less than 5% of revenues
|
12,123
|
12,362
|
Total
|
$
39,401
|
$
38,504
|
|
2018
|
2017
|
Fluid
Delivery
|
$
18,800
|
$
18,005
|
Cardiovascular
|
13,210
|
11,464
|
Ophthalmology
|
2,785
|
3,673
|
Other
|
4,606
|
5,362
|
Total
|
$
39,401
|
$
38,504
|
|
Three Months ended March 31,
|
|
|
2018
|
2017
|
|
|
|
Fluid
Delivery
|
$
18,800
|
$
18,005
|
Cardiovascular
|
13,210
|
11,464
|
Ophthalmology
|
2,785
|
3,673
|
Other
|
4,606
|
5,362
|
Total
|
$
39,401
|
$
38,504
|
Exhibit
Number
|
Description
|
Atrion
Corporation Short-Term Incentive Compensation Plan (As last amended
on March 12, 2018)
|
|
|
|
Sarbanes-Oxley Act
Section 302 Certification of Chief Executive Officer
|
|
|
|
Sarbanes-Oxley Act
Section 302 Certification of Chief Financial Officer
|
|
|
|
Certification
Pursuant To 18 U.S.C. Section 1350, As Adopted Pursuant To Section
906 of The Sarbanes – Oxley Act Of 2002
|
|
|
|
Certification
Pursuant To 18 U.S.C. Section 1350, As Adopted Pursuant To Section
906 of The Sarbanes – Oxley Act Of 2002
|
|
|
|
101.INS
|
XBRL
Instance Document
|
|
|
101.SCH
|
XBRL Taxonomy
Extension Schema Document
|
|
|
101.CAL
|
XBRL Taxonomy
Extension Calculation Linkbase Document
|
|
|
101.DEF
|
XBRL Taxonomy
Extension Definition Linkbase Document
|
|
|
101.LAB
|
XBRL Taxonomy
Extension Label Linkbase Document
|
|
|
101.PRE
|
XBRL Taxonomy
Extension Presentation Linkbase Document
|
|
Atrion Corporation
(Registrant)
|
|
|
|
|
|
|
Date: May 9, 2018 |
By:
|
/s/
David
A. Battat
|
|
|
|
David
A. Battat
|
|
|
|
President
and
Chief
Executive Officer
|
|
|
|
|
|
|
|
|
|
Date: May 9, 2018
|
By:
|
/s/
Jeffery
Strickland
|
|
|
|
Jeffery Strickland |
|
|
|
Vice
President and
Chief
Financial Officer
(Principal Accounting and
Financial Officer)
|
|
Exhibit
Number
|
Description
|
Atrion
Corporation Short-Term Incentive Compensation Plan (As last amended
on March 12, 2018)
|
|
|
|
Sarbanes-Oxley Act
Section 302 Certification of Chief Executive Officer
|
|
|
|
Sarbanes-Oxley Act
Section 302 Certification of Chief Financial Officer
|
|
|
|
Certification
Pursuant To 18 U.S.C. Section 1350, As Adopted Pursuant To Section
906 of The Sarbanes – Oxley Act Of 2002
|
|
|
|
Certification
Pursuant To 18 U.S.C. Section 1350, As Adopted Pursuant To Section
906 of The Sarbanes – Oxley Act Of 2002
|
|
|
|
101.INS
|
XBRL
Instance Document
|
|
|
101.SCH
|
XBRL
Taxonomy Extension Schema Document
|
|
|
101.CAL
|
XBRL
Taxonomy Extension Calculation Linkbase Document
|
|
|
101.DEF
|
XBRL
Taxonomy Extension Definition Linkbase Document
|
|
|
101.LAB
|
XBRL
Taxonomy Extension Label Linkbase Document
|
|
|
101.PRE
|
XBRL
Taxonomy Extension Presentation Linkbase Document
|
1 Year ATRION Chart |
1 Month ATRION Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions